

## **APAC Breast Cancer Diagnostics Market - Industry Trends and Forecast to 2030**

Market Report | 2023-01-01 | 238 pages | Data Bridge Market Research

### **AVAILABLE LICENSES:**

- Single User License \$3500.00
- Corporate Users License \$4200.00

### **Report description:**

Asia-Pacific breast cancer diagnostics market is projected to register a CAGR of 10.3% in the forecast period of 2023 to 2030. The new market report contains data for historic year 2021, the base year of calculation is 2022 and the forecast period is 2023 to 2030

### **Market Segmentation:**

Asia-Pacific Breast Cancer Diagnostics Market, By Test Type (Imaging, Biopsy, Genomic Test, Blood Test, and Others), Type (Ductal In Situ Carcinoma, Invasive Ductal Carcinoma, Inflammatory Breast Cancer, and Metastatic Breast Cancer), End User (Hospitals, Clinics, Research and Academic Institutes, Diagnostic Centres, and Others) Distribution Channel (Direct Tender, Retail Sales, and Others), Country (China, Japan, India, Australia, South Korea, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the Asia-Pacific breast cancer diagnostics market are:

- Increasing breast cancer patients among the women population as well as men
- Rise in technological advancement for breast cancer diagnostic

### **Market Players**

The key market players operating in the Asia-Pacific breast cancer diagnostics market are:

- Provista Diagnostics
- Thermo Fisher Scientific Inc.
- Myriad Genetics, Inc.
- Illumina, Inc.
- Bio-Rad Laboratories, Inc.
- BD
- NanoString.
- Cepheid

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

## **Table of Contents:**

### TABLE OF CONTENTS

|                                                                                 |    |
|---------------------------------------------------------------------------------|----|
| 1 INTRODUCTION                                                                  | 48 |
| 1.1 OBJECTIVES OF THE STUDY                                                     | 48 |
| 1.2 MARKET DEFINITION                                                           | 48 |
| 1.3 OVERVIEW OF THE ASIA PACIFIC BREAST CANCER DIAGNOSTIC MARKET                | 48 |
| 1.4 CURRENCY AND PRICING                                                        | 50 |
| 1.5 LIMITATIONS                                                                 | 50 |
| 1.6 MARKETS COVERED                                                             | 50 |
| 2 MARKET SEGMENTATION                                                           | 54 |
| 2.1 MARKETS COVERED                                                             | 54 |
| 2.2 GEOGRAPHICAL SCOPE                                                          | 55 |
| 2.3 YEARS CONSIDERED FOR THE STUDY                                              | 56 |
| 2.4 DBMR TRIPOD DATA VALIDATION MODEL                                           | 57 |
| 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS                                 | 60 |
| 2.6 MULTIVARIATE MODELLING                                                      | 61 |
| 2.7 MARKET END USER COVERAGE GRID                                               | 62 |
| 2.8 TEST TYPE LIFELINE CURVE                                                    | 63 |
| 2.9 DBMR MARKET POSITION GRID                                                   | 64 |
| 2.10 VENDOR SHARE ANALYSIS                                                      | 65 |
| 2.11 SECONDARY SOURCES                                                          | 66 |
| 2.12 ASSUMPTIONS                                                                | 66 |
| 3 EXECUTIVE SUMMARY                                                             | 67 |
| 4 PREMIUM INSIGHTS                                                              | 69 |
| 4.1 PESTEL ANALYSIS                                                             | 70 |
| 4.2 PORTER'S 5 FORCES                                                           | 71 |
| 5 EPIDEMIOLOGY                                                                  | 72 |
| 6 INDUSTRIAL INSIGHTS                                                           | 73 |
| 7 REGULATORY FRAMEWORK                                                          | 74 |
| 8 MARKET OVERVIEW                                                               | 76 |
| 8.1 DRIVERS                                                                     | 78 |
| 8.1.1 LAUNCH OF TECHNOLOGICALLY ADVANCED DIAGNOSIS & THERAPEUTICS TO AID GROWTH | 78 |
| 8.1.2 INCREASING PREVALENCE OF BREAST CANCER                                    | 78 |
| 8.1.3 GROWING IMPORTANCE OF WOMEN'S HEALTH                                      | 79 |
| 8.1.4 RISING AWARENESS TOWARDS THE BREAST CANCER                                | 79 |
| 8.2 RESTRAINTS                                                                  | 80 |
| 8.2.1 ADVERSE EFFECTS OF BREAST CANCER THERAPEUTICS                             | 80 |
| 8.2.2 HIGH COST OF THE IMAGING SYSTEMS                                          | 80 |
| 8.3 OPPORTUNITIES                                                               | 81 |
| 8.3.1 INITIATIVES TAKEN BY THE GOVERNMENT                                       | 81 |
| 8.3.2 STRATEGIC INITIATIVES TAKEN BY THE KEY MARKET PLAYERS                     | 81 |
| 8.3.3 GROWTH IN RESEARCH AND DEVELOPMENT OF BREAST CANCER                       | 82 |

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

|                                                                                            |     |
|--------------------------------------------------------------------------------------------|-----|
| 8.4 CHALLENGES                                                                             | 82  |
| 8.4.1 LACK OF DIAGNOSTIC INFRASTRUCTURE                                                    | 82  |
| 8.4.2 LACK OF SKILLED PROFESSIONALS FOR PROPER DIAGNOSIS OF BREAST CANCER                  | 83  |
| 9 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE                              | 84  |
| 9.1 OVERVIEW                                                                               | 85  |
| 9.2 IMAGING                                                                                | 88  |
| 9.2.1 IONIZING BREAST IMAGING TECHNOLOGIES                                                 | 89  |
| 9.2.1.1 FULL-FIELD DIGITAL MAMMOGRAPHY (FFDM)                                              | 90  |
| 9.2.1.2 ANALOG MAMMOGRAPHY                                                                 | 90  |
| 9.2.1.3 3D BREAST TOMOSYNTHESIS                                                            | 90  |
| 9.2.1.4 POSITRON EMISSION TOMOGRAPHY/ COMPUTED TOMOGRAPHY (PET/CT)                         | 90  |
| 9.2.1.5 MOLECULAR BREAST IMAGING/ BREAST SPECIFIC GAMMA IMAGING (MBI/BSMI)                 | 90  |
| 9.2.1.6 POSITRON EMISSION MAMMOGRAPHY                                                      | 90  |
| 9.2.1.7 OTHERS                                                                             | 90  |
| 9.2.2 NON-IONIZING IMAGING TECHNOLOGIES                                                    | 90  |
| 9.2.2.1 OPTICAL IMAGING                                                                    | 91  |
| 9.2.2.2 BREAST ULTRASOUND                                                                  | 91  |
| 9.2.2.3 BREAST MRI (MAGNETIC RESONANCE IMAGING)                                            | 91  |
| 9.2.2.4 AUTOMATED WHOLE BREAST ULTRASOUND (AWBU)                                           | 91  |
| 9.2.2.5 BREAST THERMOGRAPHY                                                                | 92  |
| 9.2.3 BIOPSY                                                                               | 92  |
| 9.2.3.1 SURGICAL BIOPSY                                                                    | 93  |
| 9.2.3.2 FINE NEEDLE ASPIRATION BIOPSY                                                      | 93  |
| 9.2.3.3 CORE NEEDLE BIOPSY                                                                 | 93  |
| 9.2.3.4 IMAGE-GUIDED BIOPSY                                                                | 93  |
| 9.2.3.5 SENTINEL LYMPH NODE BIOPSY                                                         | 94  |
| 9.2.4 GENOMIC TEST                                                                         | 94  |
| 9.2.4.1 MOLECULAR TESTING                                                                  | 95  |
| 9.2.4.1.1 PD-L1                                                                            | 96  |
| 9.2.4.1.2 MICROSATELLITE INSTABILITY-HIGH (MSI-H) OR DNA MISMATCH REPAIR DEFICIENCY (DMMR) | 96  |
| 9.2.4.1.3 NTRK GENE FUSIONS                                                                | 96  |
| 9.2.4.1.4 PI3KCA GENE MUTATION                                                             | 96  |
| 9.2.4.2 MAMMAPRINT                                                                         | 96  |
| 9.2.4.3 ONCOTYPE DX                                                                        | 96  |
| 9.2.4.4 OTHERS                                                                             | 96  |
| 9.3 BLOOD TEST                                                                             | 97  |
| 9.4 OTHERS                                                                                 | 98  |
| 10 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY TYPE                                  | 99  |
| 10.1 OVERVIEW                                                                              | 100 |
| 10.2 INVASIVE DUCTAL CARCINOMA                                                             | 103 |
| 10.3 DUCTAL CARCINOMA IN SITU                                                              | 103 |
| 10.4 INFLAMMATORY BREAST CANCER                                                            | 104 |
| 10.5 METASTATIC BREAST CANCER                                                              | 105 |
| 11 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY END USER                              | 106 |
| 11.1 OVERVIEW                                                                              | 107 |
| 11.2 HOSPITALS                                                                             | 109 |
| 11.3 DIAGNOSTICS CENTERS                                                                   | 110 |

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

|                                                                           |     |
|---------------------------------------------------------------------------|-----|
| 11.4 CLINICS                                                              | 111 |
| 11.5 RESEARCH & ACADEMIC INSTITUTES                                       | 111 |
| 11.6 OTHERS                                                               | 112 |
| 12 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL | 114 |
| 12.1 OVERVIEW                                                             | 115 |
| 12.2 DIRECT TENDER                                                        | 118 |
| 12.3 RETAIL SALES                                                         | 118 |
| 12.4 OTHERS                                                               | 119 |
| 13 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY REGION               | 120 |
| 13.1 ASIA-PACIFIC                                                         | 121 |
| 13.1.1 CHINA                                                              | 130 |
| 13.1.2 INDIA                                                              | 136 |
| 13.1.3 JAPAN                                                              | 142 |
| 13.1.4 INDONESIA                                                          | 148 |
| 13.1.5 PHILIPPINES                                                        | 154 |
| 13.1.6 THAILAND                                                           | 160 |
| 13.1.7 AUSTRALIA                                                          | 166 |
| 13.1.8 MALAYSIA                                                           | 172 |
| 13.1.9 SOUTH KOREA                                                        | 178 |
| 13.1.10 SINGAPORE                                                         | 184 |
| 13.1.11 REST OF ASIA-PACIFIC                                              | 190 |
| 14 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE       | 191 |
| 14.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC                                 | 191 |
| 15 SWOT ANALYSIS                                                          | 192 |
| 16 COMPANY PROFILE                                                        | 193 |
| 16.1 HOLOGIC, INC.                                                        | 193 |
| 16.1.1 COMPANY SNAPSHOT                                                   | 193 |
| 16.1.2 REVENUE ANALYSIS                                                   | 193 |
| 16.1.3 COMPANY SHARE ANALYSIS                                             | 194 |
| 16.1.4 PRODUCT PORTFOLIO                                                  | 194 |
| 16.1.5 RECENT DEVELOPMENTS                                                | 195 |
| 16.2 SIEMENS HEALTHCARE GMBH                                              | 196 |
| 16.2.1 COMPANY SNAPSHOT                                                   | 196 |
| 16.2.2 REVENUE ANALYSIS                                                   | 197 |
| 16.2.3 COMPANY SHARE ANALYSIS                                             | 197 |
| 16.2.4 PRODUCT PORTFOLIO                                                  | 198 |
| 16.2.5 RECENT DEVELOPMENTS                                                | 198 |
| 16.3 F. HOFFMANN- LA ROCHE LTD                                            | 199 |
| 16.3.1 COMPANY SNAPSHOT                                                   | 199 |
| 16.3.2 REVENUE ANALYSIS                                                   | 199 |
| 16.3.3 COMPANY SHARE ANALYSIS                                             | 200 |
| 16.3.4 PRODUCT PORTFOLIO                                                  | 200 |
| 16.3.5 RECENT DEVELOPMENTS                                                | 201 |
| 16.4 KONINKLIJKE PHILIPS N.V.                                             | 202 |
| 16.4.1 COMPANY SNAPSHOT                                                   | 202 |
| 16.4.2 REVENUE ANALYSIS                                                   | 202 |
| 16.4.3 COMPANY SHARE ANALYSIS                                             | 203 |

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

|         |                            |     |
|---------|----------------------------|-----|
| 16.4.4  | PRODUCT PORTFOLIO          | 203 |
| 16.4.5  | RECENT DEVELOPMENTS        | 204 |
| 16.5    | ABBOTT                     | 205 |
| 16.5.1  | COMPANY SNAPSHOT           | 205 |
| 16.5.2  | REVENUE ANALYSIS           | 205 |
| 16.5.3  | COMPANY SHARE ANALYSIS     | 206 |
| 16.5.4  | PRODUCT PORTFOLIO          | 206 |
| 16.5.5  | RECENT DEVELOPMENTS        | 206 |
| 16.6    | ABACUS ALS                 | 207 |
| 16.6.1  | COMPANY SNAPSHOT           | 207 |
| 16.6.2  | PRODUCT PORTFOLIO          | 207 |
| 16.6.3  | RECENT DEVELOPMENTS        | 207 |
| 16.7    | BD                         | 208 |
| 16.7.1  | COMPANY SNAPSHOT           | 208 |
| 16.7.2  | REVENUE ANALYSIS           | 208 |
| 16.7.3  | COMPANY SHARE ANALYSIS     | 209 |
| 16.7.4  | PRODUCT PORTFOLIO          | 209 |
| 16.7.5  | RECENT DEVELOPMENTS        | 209 |
| 16.8    | BIOCEPT, INC.              | 210 |
| 16.8.1  | COMPANY SNAPSHOT           | 210 |
| 16.8.2  | REVENUE ANALYSIS           | 210 |
| 16.8.3  | PRODUCT PORTFOLIO          | 211 |
| 16.8.4  | RECENT DEVELOPMENTS        | 211 |
| 16.9    | BIOMERIEUX                 | 212 |
| 16.9.1  | COMPANY SNAPSHOT           | 212 |
| 16.9.2  | REVENUE ANALYSIS           | 212 |
| 16.9.3  | PRODUCT PORTFOLIO          | 213 |
| 16.9.4  | RECENT DEVELOPMENTS        | 213 |
| 16.10   | BIO-RAD LABORATORIES, INC. | 214 |
| 16.10.1 | COMPANY SNAPSHOT           | 214 |
| 16.10.2 | REVENUE ANALYSIS           | 214 |
| 16.10.3 | PRODUCT PORTFOLIO          | 215 |
| 16.10.4 | RECENT DEVELOPMENT         | 215 |
| 16.11   | CEPHEID                    | 216 |
| 16.11.1 | COMPANY SNAPSHOT           | 216 |
| 16.11.2 | REVENUE ANALYSIS           | 216 |
| 16.11.3 | PRODUCT PORTFOLIO          | 217 |
| 16.11.4 | RECENT DEVELOPMENT         | 217 |
| 16.12   | EXACT SCIENCES CORPORATION | 218 |
| 16.12.1 | COMPANY SNAPSHOT           | 218 |
| 16.12.2 | REVENUE ANALYSIS           | 218 |
| 16.12.3 | COMPANY SHARE ANALYSIS     | 219 |
| 16.12.4 | PRODUCT PORTFOLIO          | 219 |
| 16.12.5 | RECENT DEVELOPMENTS        | 220 |
| 16.13   | FUJIFILM CORPORATION       | 221 |
| 16.13.1 | COMPANY SNAPSHOT           | 221 |
| 16.13.2 | REVENUE ANALYSIS           | 221 |

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

|         |                               |     |
|---------|-------------------------------|-----|
| 16.13.3 | PRODUCT PORTFOLIO             | 222 |
| 16.13.4 | RECENT DEVELOPMENT            | 222 |
| 16.14   | GENERAL ELECTRIC              | 223 |
| 16.14.1 | COMPANY SNAPSHOT              | 223 |
| 16.14.2 | REVENUE ANALYSIS              | 223 |
| 16.14.3 | PRODUCT PORTFOLIO             | 224 |
| 16.14.4 | RECENT DEVELOPMENTS           | 224 |
| 16.15   | ILLUMINA, INC.                | 225 |
| 16.15.1 | COMPANY SNAPSHOT              | 225 |
| 16.15.2 | REVENUE ANALYSIS              | 225 |
| 16.15.3 | PRODUCT PORTFOLIO             | 226 |
| 16.15.4 | RECENT DEVELOPMENTS           | 226 |
| 16.16   | MYRIAD GENETICS, INC.         | 227 |
| 16.16.1 | COMPANY SNAPSHOT              | 227 |
| 16.16.2 | REVENUE ANALYSIS              | 227 |
| 16.16.3 | PRODUCT PORTFOLIO             | 228 |
| 16.16.4 | RECENT DEVELOPMENT            | 228 |
| 16.17   | NANOSTRING.                   | 229 |
| 16.17.1 | COMPANY SNAPSHOT              | 229 |
| 16.17.2 | REVENUE ANALYSIS              | 229 |
| 16.17.3 | PRODUCT PORTFOLIO             | 230 |
| 16.17.4 | RECENT DEVELOPMENT            | 230 |
| 16.17.5 | RECENT DEVELOPMENT            | 230 |
| 16.18   | ONCOSTEM.                     | 231 |
| 16.18.1 | COMPANY SNAPSHOT              | 231 |
| 16.18.2 | PRODUCT PORTFOLIO             | 231 |
| 16.18.3 | RECENT DEVELOPMENT            | 231 |
| 16.19   | PROVISTA DIAGNOSTICS.         | 232 |
| 16.19.1 | COMPANY SNAPSHOT              | 232 |
| 16.19.2 | PRODUCT PORTFOLIO             | 232 |
| 16.19.3 | RECENT DEVELOPMENT            | 232 |
| 16.20   | THERMO FISHER SCIENTIFIC INC. | 233 |
| 16.20.1 | COMPANY SNAPSHOT              | 233 |
| 16.20.2 | REVENUE ANALYSIS              | 233 |
| 16.20.3 | PRODUCT PORTFOLIO             | 234 |
| 16.20.4 | RECENT DEVELOPMENT            | 234 |
| 17      | QUESTIONNAIRE                 | 235 |
| 18      | RELATED REPORTS               | 238 |

## APAC Breast Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Market Report | 2023-01-01 | 238 pages | Data Bridge Market Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

### ORDER FORM:

| Select license | License                 | Price     |
|----------------|-------------------------|-----------|
|                | Single User License     | \$3500.00 |
|                | Corporate Users License | \$4200.00 |
|                |                         | VAT       |
|                |                         | Total     |

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

|               |                      |                               |                                         |
|---------------|----------------------|-------------------------------|-----------------------------------------|
| Email*        | <input type="text"/> | Phone*                        | <input type="text"/>                    |
| First Name*   | <input type="text"/> | Last Name*                    | <input type="text"/>                    |
| Job title*    | <input type="text"/> |                               |                                         |
| Company Name* | <input type="text"/> | EU Vat / Tax ID / NIP number* | <input type="text"/>                    |
| Address*      | <input type="text"/> | City*                         | <input type="text"/>                    |
| Zip Code*     | <input type="text"/> | Country*                      | <input type="text"/>                    |
|               |                      | Date                          | <input type="text" value="2025-05-11"/> |
|               |                      | Signature                     | <input type="text"/>                    |

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com